Ropes & Gray advised Sanofi on the transaction, and Goodwin Procter advised Vigil Neuroscience. Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in Vigil...
Sanofi’s $40 Million Investment in Vigil Neuroscience
Ionis Pharmaceuticals’ Licensing Agreement with Otsuka
Ropes & Gray represented Ionis Pharmaceuticals in the deal. Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka)...
Nona Biosciences’ Global License and Option Agreement with AstraZeneca
Ropes & Gray advised Nona Biosciences on the deal. Nona Biosciences announced it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal...
Xeris Biopharma’s Global Collaboration and License Agreement with Beta Bionics
Ropes & Gray advised Xeris Biopharma Holdings on the transaction. Xeris Biopharma Holdings, Inc. (Nasdaq:XERS) (Xeris), a biopharmaceutical company, announced that it has entered into an exclusive worldwide...
G1 Therapeutics’ Global License Agreement with Pepper Bio
Ropes & Gray advised G1 Therapeutics, Inc. on the transaction. G1 Therapeutics (Nasdaq: GTHX) announced it has entered into a global license agreement, excluding the Asia Pacific region, with...
Teva Pharmaceuticals’ Licensing Agreement with mAbxience
Ropes & Gray represented Teva Pharmaceuticals International GmbH in the deal. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced...
Blackstone Life Sciences’ $750 Million Collaboration with Moderna
Ropes & Gray represented Blackstone Life Sciences in the transaction. Blackstone Life Sciences (NYSE:BX) (“Blackstone”) announced a collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and...
Solid Biosciences’ Licensing Agreement with Armatus Bio
Ropes & Gray advised Solid Biosciences on the transaction. Solid Biosciences (Nasdaq: SLDB), a biotechnology company specializing in genetic medicines for neuromuscular and cardiac diseases, announced...
AbbVie’s Collaboration with Umoja Biopharma
Ropes & Gray advised AbbVie on the deal. AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja) Umoja Biopharma announced two exclusive option and license agreements to develop multiple in-situ...
ImmunoGen’s Collaboration with Takeda
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited (TSE:...
Verastem Oncology’s Collaboration with GenFleet Therapeutics
Ropes & Gray advised Verastem Oncology on the deal. Verastem Oncology (Nasdaq: VSTM) announced that the company has entered into a discovery and development collaboration with...
ImmunoGen’s Multi-Target License and Option Agreement with ImmunoBiochem
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation on the...